Show simple item record

dc.contributor.authorRos, S
dc.contributor.authorWright, AJ
dc.contributor.authorBruna, A
dc.contributor.authorCaldas, C
dc.contributor.authorBrindle, KM
dc.date.accessioned2021-07-13T15:19:11Z
dc.date.available2021-07-13T15:19:11Z
dc.identifier.citationSTAR protocols, 2021, 2 (3), pp. 100608 - ?
dc.identifier.issn2666-1667
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4685
dc.identifier.eissn2666-1667
dc.identifier.doi10.1016/j.xpro.2021.100608
dc.description.abstract13 C nuclear spin hyperpolarization can increase the sensitivity of detection in an MRI experiment by more than 10,000-fold. 13 C magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13 C label exchange between injected [1- 13 C]pyruvate and the endogenous tumor lactate pool can be used clinically to assess tumor grade and response to treatment. We describe here an experimental protocol for using this technique in patient-derived and established cell line xenograft models of breast cancer in the mouse. For complete details on the use and execution of this protocol, please refer to Ros et al. (2020).
dc.formatElectronic-eCollection
dc.format.extent100608 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleMetabolic imaging with hyperpolarized [1-<sup>13</sup>C] pyruvate in patient-derived preclinical mouse models of breast cancer.
dc.typeJournal Article
dcterms.dateAccepted2021-09-17
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.xpro.2021.100608
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSTAR protocols
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.publication-statusAccepted
pubs.volume2
pubs.embargo.termsNot known
icr.researchteamPreclinical Modelling of Paediatric Cancer Evolution
icr.researchteamPreclinical Modelling of Paediatric Cancer Evolutionen_US
dc.contributor.icrauthorBruna Cabot, Alejandraen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0